The shares of SCHOTT Pharma, a global market leader for drug containment solutions and delivery systems, will be included in the MDAX, a stock index which lists German companies trading on the Frankfurt Stock Exchange, for the first time as of September 23, 2024.
Andreas Reisse, CEO of SCHOTT Pharma, said, “We are delighted that less than one year after our IPO and nine months in the SDAX we are moving up to the next league. The MDAX entry is further proof of the continued confidence of our investors in our business model and our strategy. We look forward to building on this next milestone.”
As part of the 90 most important prime standard shares listed on the Frankfurt stock exchange, the MDAX index comprises the 50 largest and most liquid companies following the DAX in terms of market capitalization.
SCHOTT Pharma (WKN A3ENQ5, ISIN DE000A3ENQ51) has been listed on the Frankfurt Stock Exchange since September 2023 and part of the SDAX since December 2023.
Dr. Almuth Steinkühler, CFO of SCHOTT Pharma, said, “Today is yet another special day for SCHOTT Pharma. We are excited about joining the MDAX and further strengthening our position and visibility in the capital market. The promotion to the MDAX is proof of our strong financial performance and offers SCHOTT Pharma the best conditions to further achieve its ambitious growth targets.”
The company announced its Q3 2024 results on August 29, 2024, and will publish its annual report for the fiscal year 2024 on December 12, 2024.